Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre.

Abdolrasouli A, Scourfield A, Rhodes J, Shah A, Elborn JS, Fisher MC, Schelenz S, Armstrong-James D.

Int J Antimicrob Agents. 2018 Nov;52(5):637-642. doi: 10.1016/j.ijantimicag.2018.08.004. Epub 2018 Aug 10.

PMID:
30103005
2.

A Prospective Real-World Study of the Impact of an Antifungal Stewardship Program in a Tertiary Respiratory-Medicine Setting.

Nwankwo L, Periselneris J, Cheong J, Thompson K, Darby P, Leaver N, Schelenz S, Armstrong-James D.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00402-18. doi: 10.1128/AAC.00402-18. Print 2018 Oct.

3.

Author Correction: Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris.

Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S.

Emerg Microbes Infect. 2018 May 31;7(1):104. doi: 10.1038/s41426-018-0098-x.

4.

Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis.

Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AYY, de Boer LL, Shah A, Milburn AJ, Elborn JS, Jones AL, Meis JF, Fisher MC, Schelenz S, Simmonds NJ, Armstrong-James D.

Mycoses. 2018 Apr 27. doi: 10.1111/myc.12789. [Epub ahead of print]

PMID:
29702751
5.

Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris.

Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S.

Emerg Microbes Infect. 2018 Mar 29;7(1):43. doi: 10.1038/s41426-018-0045-x. Erratum in: Emerg Microbes Infect. 2018 May 31;7(1):104.

6.

Candida auris: a Review of the Literature.

Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A; Candida auris Incident Management Team, Manuel R, Brown CS.

Clin Microbiol Rev. 2017 Nov 15;31(1). pii: e00029-17. doi: 10.1128/CMR.00029-17. Print 2018 Jan. Review.

7.

An investigation of antifungal stewardship programmes in England.

Micallef C, Ashiru-Oredope D, Hansraj S, Denning DW, Agrawal SG, Manuel RJ, Schelenz S, Guy R, Muller-Pebody B, Patel R, Howard P, Hopkins S, Johnson E, Enoch DA.

J Med Microbiol. 2017 Nov;66(11):1581-1589. doi: 10.1099/jmm.0.000612. Epub 2017 Oct 25.

8.

In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris.

Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S.

Mycoses. 2017 Nov;60(11):758-763. doi: 10.1111/myc.12699. Epub 2017 Sep 15.

PMID:
28872735
9.

Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris.

Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS.

J Hosp Infect. 2017 Dec;97(4):371-375. doi: 10.1016/j.jhin.2017.08.019. Epub 2017 Sep 1.

PMID:
28865738
10.

Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients.

Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S, Collins S, Del Ojo Elias C, Ahmed N, Brown T, Smith EG, Hoffman P, Kirwan P, Mason B, Smith-Palmer A, Veal P, Lalor MK, Bennett A, Walker J, Yeap A, Isidro Carrion Martin A, Dolan G, Bhatt S, Skingsley A, Charlett A, Pearce D, Russell K, Kendall S, Klein AA, Robins S, Schelenz S, Newsholme W, Thomas S, Collyns T, Davies E, McMenamin J, Doherty L, Peto TE, Crook D, Zambon M, Phin N.

Clin Infect Dis. 2017 Feb 1;64(3):335-342. doi: 10.1093/cid/ciw754. Epub 2016 Dec 7.

11.

First hospital outbreak of the globally emerging Candida auris in a European hospital.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC.

Antimicrob Resist Infect Control. 2016 Oct 19;5:35. eCollection 2016.

12.

A Sweet Response to a Sour Situation: The Role of Soluble Pattern Recognition Receptors in the Innate Immune Response to Invasive Aspergillus fumigatus Infections.

Bidula S, Schelenz S.

PLoS Pathog. 2016 Jul 14;12(7):e1005637. doi: 10.1371/journal.ppat.1005637. eCollection 2016 Jul. Review. No abstract available.

13.

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, Wierre-Gore N, Alton EW, Bundy JG, Connett G, Faust SN, Filloux A, Freemont P, Jones A, Khoo V, Morales S, Murphy R, Pabary R, Simbo A, Schelenz S, Takats Z, Webb J, Williams HD, Davies JC.

Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13. Review.

14.

Serum opsonin ficolin-A enhances host-fungal interactions and modulates cytokine expression from human monocyte-derived macrophages and neutrophils following Aspergillus fumigatus challenge.

Bidula S, Sexton DW, Schelenz S.

Med Microbiol Immunol. 2016 Apr;205(2):133-42. doi: 10.1007/s00430-015-0435-9. Epub 2015 Sep 4.

PMID:
26337048
15.

H-ficolin binds Aspergillus fumigatus leading to activation of the lectin complement pathway and modulation of lung epithelial immune responses.

Bidula S, Sexton DW, Yates M, Abdolrasouli A, Shah A, Wallis R, Reed A, Armstrong-James D, Schelenz S.

Immunology. 2015 Oct;146(2):281-91. doi: 10.1111/imm.12501. Epub 2015 Aug 24.

16.

British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.

Schelenz S, Barnes RA, Barton RC, Cleverley JR, Lucas SB, Kibbler CC, Denning DW; British Society for Medical Mycology.

Lancet Infect Dis. 2015 Apr;15(4):461-74. doi: 10.1016/S1473-3099(15)70006-X. Epub 2015 Mar 12. Review.

PMID:
25771341
17.

The serum opsonin L-ficolin is detected in lungs of human transplant recipients following fungal infections and modulates inflammation and killing of Aspergillus fumigatus.

Bidula S, Sexton DW, Abdolrasouli A, Shah A, Reed A, Armstrong-James D, Schelenz S.

J Infect Dis. 2015 Jul 15;212(2):234-46. doi: 10.1093/infdis/jiv027. Epub 2015 Jan 22.

PMID:
25612732
18.

Sustainable intensive thermal use of the shallow subsurface-a critical view on the status quo.

Vienken T, Schelenz S, Rink K, Dietrich P.

Ground Water. 2015 May-Jun;53(3):356-61. doi: 10.1111/gwat.12206. Epub 2014 May 14.

PMID:
24826995
19.

Unilateral cacosmia: a presentation of maxillary fungal infestation.

Erskine SE, Schelenz S, Philpott CM.

BMJ Case Rep. 2013 Apr 5;2013. pii: bcr2013008808. doi: 10.1136/bcr-2013-008808.

20.

Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species.

Bidula S, Kenawy H, Ali YM, Sexton D, Schwaeble WJ, Schelenz S.

Infect Immun. 2013 May;81(5):1730-40. doi: 10.1128/IAI.00032-13. Epub 2013 Mar 11.

21.

Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance.

Schelenz S, Nwaka D, Hunter PR.

J Antimicrob Chemother. 2013 Jun;68(6):1431-8. doi: 10.1093/jac/dkt002. Epub 2013 Feb 8.

PMID:
23396855
22.

An antibiotic formulary for a tertiary care foot clinic: admission avoidance using intramuscular antibiotics for borderline foot infections in people with diabetes.

Gooday C, Hallam C, Sieber C, Mtariswa L, Turner J, Schelenz S, Murchison R, Messenger G, Morrow D, Hutchinson R, Williams H, Dhatariya K.

Diabet Med. 2013 May;30(5):581-9. doi: 10.1111/dme.12074. Epub 2013 Feb 28.

PMID:
23210933
23.

Opsonizing properties of rat ficolin-A in the defence against Cryptococcus neoformans.

Schelenz S, Kirchhof N, Bidula S, Wallis R, Sexton DW.

Immunobiology. 2013 Apr;218(4):477-83. doi: 10.1016/j.imbio.2012.06.006. Epub 2012 Jun 21.

PMID:
22789560
24.

Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.

Schelenz S, Giles D, Abdallah S.

Ann Oncol. 2012 Jul;23(7):1889-93. doi: 10.1093/annonc/mdr520. Epub 2011 Nov 2.

PMID:
22048152
25.

In vitro antifungal activity of DNA topoisomerase inhibitors.

Steverding D, Evans P, Msika L, Riley B, Wallington J, Schelenz S.

Med Mycol. 2012 Apr;50(3):333-6. doi: 10.3109/13693786.2011.609186. Epub 2011 Sep 22.

PMID:
21939347
26.

Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors.

Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, Hunter PR.

J Oral Pathol Med. 2011 Jan;40(1):83-9. doi: 10.1111/j.1600-0714.2010.00937.x. Epub 2010 Oct 4.

PMID:
20923440
27.

Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system.

Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S.

Emerg Infect Dis. 2010 Jul;16(7):1185-6. doi: 10.3201/eid1607.091579. No abstract available.

28.

In vitro effect of DNA topoisomerase inhibitors on Candida albicans.

Kwok SC, Schelenz S, Wang X, Steverding D.

Med Mycol. 2010 Feb;48(1):155-60. doi: 10.3109/13693780903114934.

PMID:
19626543
29.

Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit.

Schelenz S, Barnes RA, Kibbler CC, Jones BL, Denning DW.

J Infect. 2009 Feb;58(2):145-53. doi: 10.1016/j.jinf.2008.12.006. Epub 2009 Jan 29.

PMID:
19185349
30.

Management of candidiasis in the intensive care unit.

Schelenz S.

J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i31-4. doi: 10.1093/jac/dkm430. Review.

PMID:
18063602
31.

Internet treatment of sexually transmitted infections - a public health hazard?

Vivancos R, Schelenz S, Loke YK.

BMC Public Health. 2007 Nov 15;7:333.

32.

A systematic review of the clinical, public health and cost-effectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food.

Abubakar I, Irvine L, Aldus CF, Wyatt GM, Fordham R, Schelenz S, Shepstone L, Howe A, Peck M, Hunter PR.

Health Technol Assess. 2007 Sep;11(36):1-216. Review.

33.

Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae.

Schelenz S, Bramham K, Goldsmith D.

Joint Bone Spine. 2007 May;74(3):275-8. Epub 2007 Mar 15. Review.

PMID:
17433752
34.
35.

Streptococcus mutans endocarditis: beware of the 'diphtheroid'.

Schelenz S, Page AJ, Emmerson AM.

J R Soc Med. 2005 Sep;98(9):420-1. No abstract available.

36.

Diagnosis and treatment of fungal endophthalmitis: a reassessment.

Schelenz S, Watson N.

Clin Infect Dis. 2005 Jul 15;41(2):274-5; author reply 275-6. No abstract available.

PMID:
15983936
37.

Significant reduction of endemic MRSA acquisition and infection in cardiothoracic patients by means of an enhanced targeted infection control programme.

Schelenz S, Tucker D, Georgeu C, Daly S, Hill M, Roxburgh J, French GL.

J Hosp Infect. 2005 Jun;60(2):104-10.

PMID:
15866007
38.

Portal vein thrombosis despite anticoagulation in a person with diabetes.

Schweigart JH, Klotsas A, Schelenz S, Dhatariya K.

J R Soc Med. 2005 Apr;98(4):161-3. Review. No abstract available.

39.

Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period.

Schelenz S, Gransden WR.

Mycoses. 2003;46(9-10):390-6.

PMID:
14622387
40.
41.

Infective endocarditis in dialysis patients: new challenges and old.

Doulton T, Sabharwal N, Cairns HS, Schelenz S, Eykyn S, O'Donnell P, Chambers J, Austen C, Goldsmith DJ.

Kidney Int. 2003 Aug;64(2):720-7.

43.

Hospital Infection Society International Activities. Argentina - British infection control experience.

Schelenz S.

J Hosp Infect. 2000 Apr;44(4):317-8. No abstract available.

PMID:
10772839
45.

Supplemental Content

Loading ...
Support Center